NSCLC）确定的驱动突变基因，EGFR最常见的典型突变是19外显子缺失突变（exon 19 deletion, Ex19del）和21外显子氨基酸替换L858R的错义突变（exon 21 point mutation, L858R），携带此类突变的NSCLC患者对酪氨酸激酶抑制剂（tyrosine kinase
[29]N. Girard, K. Park, K. Tang, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON...
表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是我国肺癌人群最常见的致癌驱动突变,约占 51.7%～54.4%,远高于高加索人群(10%～16.6%)。EGFR 20 号外显子插入突变(exon20 insertion mutation,ex20ins)发生率居 EGFR 基因突变第 3 位,仅次于 19 号外显子缺失突变(ex19del)和 21 号外显子 L...
13.H.l. Chen, et al. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS). 2024 WCLC WS02.12. 14.Baohui Han, et al. Furmonertinib Combined with...
[3]Liu J, Xiang Y, Fang T, et al. Advances in the diagnosis and treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mutation. Clinical Lung Cancer, 2023. doi: 10.1016/j.cllc.2023.11.010. Available online 23 November 2023. ...
[11]Li X, Zhang L, Jiang D, et al. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial[J]. Clin Cancer Res. 2020, 26(13):3162-3171. ...
胞质结构域包括较小的N端叶(N-terminal lobe)和较大的C端叶(C-terminal lobe),由ATP结合间隙隔开。配体与EGFR结合会触发二聚化,激活激酶结构域并启动下游信号通路(图4A)。NSCLC中常见的EGFR突变包括 19号外显子缺失(exon19del)和21号外显子L858R,合计占NSCLC中观察到的EGFR突变的 85%。
[9]Yuki Sato, Satoru Miura, Toshihiro Misumi, et al. Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naive non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG18...
10. Naidoo, J., et al., Epidermal growth factor receptor exon 20 insertions in advanced lung ...
21.Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024;12(3):...